Trivalent inactivated influenza virus vaccine given to two-month-old children: An off-season pilot study

Pediatric Infectious Disease Journal

Volumn 28, Issue 12, 2009, Pages 1099-1104

  Walter, Emmanuel B ^a   Englund, Janet A ^b   Blatter, Mark ^c   Nyberg, Jack ^d   Ruben, Frederick L ^d   Decker, Michael D ^d,e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Primary Physicians Research   (United States)

^d SANOFI PASTEUR   (France)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Immunogenicity; Infants; Influenza; Vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

ABNORMAL CRYING; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CRYING; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; IRRITABILITY; MALE; MULTICENTER STUDY; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; RASH; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS STRAIN;

EID: 74049098199     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181b0c0ca     Document Type: Article

References (28)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186. (Pubitemid 36068705)
2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospi-talizations in the United States. JAMA. 2004;292:1333-1340.
3. Izurieta HS, Thompson WW, Kramer P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-239.
4. Neuzil KM, Mellen BG, Wright PF. The impact of influenza on hospital-izations, outpatient visits, and antibiotic prescriptions in children. N Engl J Med. 2000;342:225-231.
5. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;133:585-593.
6. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31-40
7. CDC. Surveillance for laboratory-confirmed, influenza-associated hospital-izations-Colorado, 2004-2005 influenza season. MMWR. 2005;54:535-537.
8. CDC. Update. Influenza activity-United States and worldwide, 2003-2004 season, and composition of the 2004-05 influenza vaccine. MMWR. 2004; 53:547-552.
9. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353:2559-2567.
10. Neuzil KM, Dupont WD, Wright PF. The efficacy of inactivated and cold-adapted vaccines against influenza A infection 1985-1990: the pedi-atric experience. Pediatr Infect Dis. 2001;20:733-740.
11. Hurwitz ES, Haber M, Chang A. Studies of the 1996-1997 inactivated influenza vaccine among children attending daycare. J Infect Dis. 2000; 182:1218-1221.
12. American Lung Association; Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 2001;345:1529-1536.
13. Clements DA, Langdon L, Bland C, et al. Influenza A vaccine decreases the incidence of otitis media in 6-36-month old children in day care. Arch Pediatr Adolesc Med. 1995;149:1113-1117.
14. Hoberman A, Greenberg DP, Paradise JL, et al. Efficacy of inactivated influenza vaccine in preventing acute otitis media in children. JAMA. 2003;290:1608-1616.
15. Englund JA, Walter EB, Fairchok MP, et al. A comparison of two influenza vaccine schedules in 6-23 month-old children. Pediatrics. 2005;115:1039-1047.
16. Walter EB, Neuzil KM, Zhu Y, et al. Influenza vaccine immunogenicity in 6-to 23-month-old children: are identical antigens necessary for priming? Pediatrics. 2006;118:e570-e578.
17. Englund JA, Walter EB, Gbadebo A, et al. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics. 2006;118:e579-e585.
18. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR-10): 1-42.
19. Groothuis JR, Levin MJ, Rabalais GP, et al. Immunization of high-risk infants younger than 18 months with split product influenza vaccine. Pediatrics. 1991;87:823-828.
20. Halasa NB, Gerber MA, Chen Q, et al. Safety and immunogenicity of trivalent influenza vaccine in infants. J Infect Dis. 2008;197:1448-1454.
21. Falsey AR, Treanor JJ, Torneieporth N, et al. Superior immunogenicity of high dose influenza vaccine compared with standard influenza vaccine in adults >65 years of age: a randomized double-blind controlled phase 3 trial. J Infect Dis. In press.
22. Piedra PA, Glezen WP, Mbawuike I, et al. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine. 1993;11:718-724.
23. Letson GW, Shapiro CN, Kuehn D, et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr. 2004;144: 327-332.
24. Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J. 2000;19:1045-1052.
25. Gans HA, Arvin AM, Galinus J, et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA. 1998;280:527-532.
26. Update: Influenza Activity-United States, 2004-2005 Season. MMWR. 2005; 54: 328-331.
27. Davies JR, Grilli EA. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect. 1989;102:325-333.
28. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006;194:1032-1039.